Objective: To analyze the safety and efficacy of different periods of preoperative adjuvant chemotherapy (SOX) regimen in the treatment of advanced gastric cancer.
From June 1 2010 to June 1 2017, 120 patients aged from 25 to 80 with clinical stage IIA-IIIC gastric cancer received neoadjuvant chemotherapy with S-1 and oxaliplatin and gastrectomy in Chinese PLA General Hospital. Patients were randomly assigned to two groups with different length of treatment in preoperative neoadjuvant chemotherapy. There were 60 patients in the group with 3 periods preoperative neoadjuvant chemotherapy of treatment, and 60 patients in the group with 5 periods preoperative neoadjuvant chemotherapy of treatment. An ambispective cohort study was conducted. We compared short-term surgical outcomes between the two groups.
There was no significant difference in clinical pathological features between the two groups. However, the five-cycle group had less operative time (229 minutes vs 240 minutes, P = 0.031) and less intraoperative blood loss (158 ml vs. 201 ml, P = 0.006). The short-term prognosis was similar in both groups. The R0 resection rate was higher in the 5-cycle group, especially in stage III subgroup.
The longer preoperative chemotherapy in neoadjuvant chemotherapy, the better the effect of the neoadjuvant chemotherapy in patients with advanced gastric cancer, so we can try to use more preoperative neoadjuvant chemotherapy.
Clinical trial identification
Legal entity responsible for the study
Chinese PLA general hospital.
Chinese national nature science foundation and Beijing\'s NOVO programme.
The author has declared no conflicts of interest.